(NASDAQ: GLMD) Galmed Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.87%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.28%.
Galmed Pharmaceuticals's earnings in 2026 is -$10,309,000.On average, 3 Wall Street analysts forecast GLMD's earnings for 2026 to be -$10,472,308, with the lowest GLMD earnings forecast at -$10,061,629, and the highest GLMD earnings forecast at -$10,780,317. On average, 3 Wall Street analysts forecast GLMD's earnings for 2027 to be -$6,041,716, with the lowest GLMD earnings forecast at -$5,804,786, and the highest GLMD earnings forecast at -$6,219,414.
In 2028, GLMD is forecast to generate -$5,101,894 in earnings, with the lowest earnings forecast at -$4,901,819 and the highest earnings forecast at -$5,251,949.